Zepzelca is a drug owned by Jazz Pharmaceuticals Ireland Ltd. It is protected by 4 US drug patents filed from 2020 to 2025 out of which none have expired yet. Zepzelca's patents have been open to challenges since 15 June, 2024. Based on its patents and exclusivities, its generic launch date is estimated to be May 29, 2040. Details of Zepzelca's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7763615 | Ecteinascidin analogs for use as antitumour agents |
Dec, 2029
(3 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12433890 | Method Of Treating Sclc And Managing Neutropenia |
May, 2040
(13 years from now) | Active |
| US12324806 | Method of treating SCLC and managing hepatotoxicity |
May, 2040
(13 years from now) | Active |
| US12440490 | Method Of Treating Sclc And Managing Thrombocytopenia |
May, 2040
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Zepzelca's patents.
Latest Legal Activities on Zepzelca's Patents
Given below is the list of recent legal activities going on the following patents of Zepzelca.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Miscellaneous Communication to Applicant | 29 Oct, 2025 | US12440490 |
| Email Notification | 29 Oct, 2025 | US12440490 |
| Miscellaneous Communication to Applicant - No Action Count | 28 Oct, 2025 | US12440490 |
| Recordation of Patent Grant Mailed | 21 Oct, 2025 | US12440490 |
| Recordation of Patent Grant Mailed | 14 Oct, 2025 | US12433890 |
| Patent eGrant Notification | 14 Oct, 2025 | US12440490 |
| Recordation of Patent eGrant | 14 Oct, 2025 | US12440490 |
| Mail Patent eGrant Notification | 14 Oct, 2025 | US12440490 |
| Email Notification | 14 Oct, 2025 | US12440490 |
| Patent Issue Date Used in PTA Calculation | 14 Oct, 2025 | US12440490 |
FDA has granted several exclusivities to Zepzelca. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Zepzelca, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Zepzelca.
Exclusivity Information
Zepzelca holds 3 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Zepzelca's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
| New Indication(I-977) | Oct 02, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Zepzelca is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zepzelca's family patents as well as insights into
ongoing legal events
on those patents.
Zepzelca's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Zepzelca:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Zepzelca's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 29, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zepzelca Generics:
There are no approved generic versions for Zepzelca as of now.
How can I launch a generic of Zepzelca before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Zepzelca's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zepzelca's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Zepzelca -
| Strength | Submission Date | Expiration Date of Last Qualifying Patent | 180-Day Status | First Applicant Approval | Generic Competition Status |
|---|---|---|---|---|---|
| 17 Jun, 2024 | 13 Dec, 2029 | Moderate |
About Zepzelca
Zepzelca is a drug owned by Jazz Pharmaceuticals Ireland Ltd. It is used for treating small cell lung cancer in adult patients who have progressed on or after platinum-based chemotherapy. Zepzelca uses Lurbinectedin as an active ingredient. Zepzelca was launched by Jazz in 2020.
Approval Date:
Zepzelca was approved by FDA for market use on 15 June, 2020.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Zepzelca is 15 June, 2020, its NCE-1 date is estimated to be 15 June, 2024.
Active Ingredient:
Zepzelca uses Lurbinectedin as the active ingredient. Check out other Drugs and Companies using Lurbinectedin ingredient
Treatment:
Zepzelca is used for treating small cell lung cancer in adult patients who have progressed on or after platinum-based chemotherapy.
Dosage:
Zepzelca is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 4MG/VIAL | POWDER | Prescription | INTRAVENOUS |